Cheng XUE, Chen-chen ZHOU, Chang-lin MEI. Prognostic Evaluation and Treatment of Autosomal Dominant Polycystic Kidney Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(1): 75-80. doi: 10.3969/j.issn.1674-9081.2018.01.014
Citation: Cheng XUE, Chen-chen ZHOU, Chang-lin MEI. Prognostic Evaluation and Treatment of Autosomal Dominant Polycystic Kidney Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(1): 75-80. doi: 10.3969/j.issn.1674-9081.2018.01.014

Prognostic Evaluation and Treatment of Autosomal Dominant Polycystic Kidney Disease

doi: 10.3969/j.issn.1674-9081.2018.01.014
  • Received Date: 2017-05-01
  • Publish Date: 2018-01-30
  • The prevalence of autosomal dominant polycystic kidney disease(ADPKD) is 1‰ to 2‰, belonging to rare diseases. ADPKD is mainly manifested as gradually developing bilateral renal cysts, progressively increasing renal size, and gradually reduced renal function. PKD1 mutation accounts for about 81%; PKD2 mutation accounts for about 10.5% to 22%. Vasopressin and cyclic adenosine monophosphate(cAMP) signaling pathways play an important role in the development of ADPKD cysts. In recent years, the Mayo risk assessment model and predicting renal outcome in polycystic kidney disease(PROPKD) score, which are good prognostic models for ADPKD, have become important evidences for clinical decision-making. Tolvaptan, which inhibits cAMP pathway by antagonizing vasopressin receptor, has become the first specific treatment for ADPKD. Tolvaptan could effectively inhibit the growth of total renal size, and protect renal function. Long-term safety of the drug still needs further study.
  • loading
  • [1] Neumann HP, Jilg C, Bacher J, et al. Epidemiology of autosomal-dominant polycystic kidney disease:an in-depth clinical study for south-western Germany[J]. Nephrol Dial Transplant, 2013, 28:1472-1487. doi:  10.1093/ndt/gfs551
    [2] Xue C, Zhou CC, Wu M, et al. The clinical manifestation and management of autosomal dominant polycystic kidney disease in China[J]. Kidney Dis(Basel), 2016, 2:111-119. doi:  10.1159/000449030
    [3] Ong AC, Devuyst O, Knebelmann B, et al. Autosomal dominant polycystic kidney disease:the changing face of clinical management[J]. Lancet, 2015, 385:1993-2002. doi:  10.1016/S0140-6736(15)60907-2
    [4] Sommerer C, Zeier M. Clinical manifestation and manage-ment of ADPKD in western countries[J]. Kidney Dis(Basel), 2016, 2:120-127. doi:  10.1159/000449394
    [5] Steinman TI. Polycystic kidney disease:a 2011 update[J]. Curr Opin Nephrol Hypertens, 2012, 21:189-194. doi:  10.1097/MNH.0b013e32835011a7
    [6] Mao Z, Chong J, Ong AC. Autosomal dominant polycystic kidney disease:recent advances in clinical management[J]. F1000Res, 2016, 5:2029. doi:  10.12688/f1000research.9045.1
    [7] Chen L, Zhou X, Fan LX, et al. Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease[J]. J Clin Invest, 2015, 125:2399-2412. doi:  10.1172/JCI80467
    [8] Ong AC, Harris PC. Molecular pathogenesis of ADPKD:the polycystin complex gets complex[J]. Kidney Int, 2005, 67:1234-1247. doi:  10.1111/j.1523-1755.2005.00201.x
    [9] Porath B, Gainullin VG, Cornec-Le Gall E, et al. Mutations in GANAB, encoding the glucosidase Ⅱα subunit, cause autosomal-dominant polycystic kidney and liver disease[J]. Am J Hum Genet, 2016, 98:1193-1207. doi:  10.1016/j.ajhg.2016.05.004
    [10] Audrezet MP, Cornec-Le Gall E, Chen JM, et al. Autosomal dominant polycystic kidney disease:comprehensive mutation analysis of PKD1 and PKD2 in 700 unrelated patients[J]. Hum Mutat, 2012, 33:1239-1250. doi:  10.1002/humu.22103
    [11] Ong AC, Harris PC. A polycystin-centric view of cyst formation and disease:the polycystins revisited[J]. Kidney Int, 2015, 88:699-710. doi:  10.1038/ki.2015.207
    [12] Harris PC, Torres VE. Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease[J]. J Clin Invest, 2014, 124:2315-2324. doi:  10.1172/JCI72272
    [13] Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease[J]. N Engl J Med, 2006, 354:2122-2130. doi:  10.1056/NEJMoa054341
    [14] Chapman AB, Bost JE, Torres VE, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease[J]. Clin J Am Soc Nephrol, 2012, 7:479-486. doi:  10.2215/CJN.09500911
    [15] Bhutani H, Smith V, Rahbari-Oskoui F, et al. A compar-ison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease[J]. Kidney Int, 2015, 88:146-151. doi:  10.1038/ki.2015.71
    [16] Pei Y, Obaji J, Dupuis A, et al. Unified criteria for ultrasonographic diagnosis of ADPKD[J]. J Am Soc Nephrol, 2009, 20:205-212. doi:  10.1681/ASN.2008050507
    [17] Simms RJ, Travis DL, Durkie M, et al. Genetic testing in the assessment of living related kidney donors at risk of autosomal dominant polycystic kidney disease[J]. Transplanta-tion, 2015, 99:1023-1029. doi:  10.1097/TP.0000000000000466
    [18] Zong C, Lu S, Chapman AR, et al. Genome-wide detection of single-nucleotide and copy-number variations of a single human cell[J]. Science, 2012, 338:1622-1626. doi:  10.1126/science.1229164
    [19] Chapman AB, Devuyst O, Eckardt KU, et al. Autosomal-dominant polycystic kidney disease(ADPKD):executive summary from a Kidney Disease:Improving Global Outcomes(KDIGO) Controversies Conference[J]. Kidney Int, 2015, 88:17-27. doi:  10.1038/ki.2015.59
    [20] Schrier RW, Brosnahan G, Cadnapaphornchai MA, et al. Predictors of autosomal dominant polycystic kidney disease progression[J]. J Am Soc Nephrol, 2014, 25:2399-2418. doi:  10.1681/ASN.2013111184
    [21] Cornec-Le Gall E, Audrezet MP, Rousseau A, et al. The PROPKD score:a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease[J]. J Am Soc Nephrol, 2016, 27:942-951. doi:  10.1681/ASN.2015010016
    [22] Irazabal MV, Rangel LJ, Bergstralh EJ, et al. Imaging classification of autosomal dominant polycystic kidney disease:a simple model for selecting patients for clinical trials[J]. J Am Soc Nephrol, 2015, 26:160-172. doi:  10.1681/ASN.2013101138
    [23] Xue C, Zhou C, Dai B, et al. Antihypertensive treatments in adult autosomal dominant polycystic kidney disease:network meta-analysis of the randomized controlled trials[J]. Oncotarget, 2015, 6:42515-42529. doi:  10.18632/oncotarget.6452
    [24] Torres VE, Abebe KZ, Chapman AB, et al. Angiotensin blockade in late autosomal dominant polycystic kidney disease[J]. N Engl J Med, 2014, 371:2267-2276. doi:  10.1056/NEJMoa1402686
    [25] Walz G, Budde K, Mannaa M, et al. Everolimus in patients with autosomal dominant polycystic kidney disease[J]. N Engl J Med, 2010, 363:830-840. doi:  10.1056/NEJMoa1003491
    [26] Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease[J]. N Engl J Med, 2010, 363:820-829. doi:  10.1056/NEJMoa0907419
    [27] Caroli A, Perico N, Perna A, et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease(ALADIN):a randomised, placebo-controlled, multicentre trial[J]. Lancet, 2013, 382:1485-1495. doi:  10.1016/S0140-6736(13)61407-5
    [28] Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease[J]. N Engl J Med, 2012, 367:2407-2418. doi:  10.1056/NEJMoa1205511
    [29] Torres VE, Chapman AB, Devuyst O, et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease:the TEMPO 4:4 Trial[J]. Nephrol Dial Transplant, 2017. doi: 10.1093/ndt/gfx043.[Epub ahead of print].
    [30] Torres VE, Higashihara E, Devuyst O, et al. Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage:results from the TEMPO 3:4 trial[J]. Clin J Am Soc Nephrol, 2016, 11:803-811. doi:  10.2215/CJN.06300615
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(1)

    Article Metrics

    Article views (262) PDF downloads(149) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return